Combination vaccine against measles, mumps, rubella, and varicella viruses
Pharmaceutical compound
TheMMRV vaccine is a combinationvaccine againstmeasles ,mumps ,rubella (German measles), andvaricella (chickenpox).[ 6] [ 7] measles vaccine ,mumps vaccine ,rubella vaccine , andvaricella vaccine into asingle injection .[ 6] [ 7] immunogenicity and overall safety profiles to theMMR vaccine administered with or without the varicella vaccine. The MMRV vaccine is typically given to children between one and two years of age.[ 8]
Several companies supply MMRV vaccines. Proquad is marketed byMerck and was approved in 2005, for use in the United States for children aged twelve months of age through twelve years of age.[ 6] measles ,mumps ,rubella , andvaricella vaccines had been previously licensed in 1963, 1967, 1969, and 1995, respectively.[ 9] [ 10] [ 11] [ 12] GlaxoSmithKline is available in some of the member states of the European Union.[ 13] [ 14] [ 15] [ 16]
The MMRV vaccine, a combined MMR and varicella vaccine, simplifies the administration of the vaccines.[ 17]
Rare but serious adverse events reported following Proquad vaccination includeallergic reactions , including swelling of the lips, tongue, or face; difficulty breathing or closing of the throat;hives ; paleness; weakness; dizziness; a fast heartbeat;deafness ; long-term seizures, coma, or lowered consciousness; seizures (jerking or staring) caused by fever; or temporary low platelet count.[ 18]
For children aged two and younger, the MMRV vaccine is associated with significantly moreadverse events compared to separate administration of MMR and varicella vaccinations on the same day.[ 18] febrile seizures per 10,000 vaccinated children (95% CI 2.6–5.6), 7.5 additional mostly mild fever episodes per 100 vaccinated children (95% CI, 5.4–9.4) and 1.1 additional measles-like rash per 100 children (95% CI, 0.2–1.8). Febrile seizures caused by the MMRV vaccine occur 7 to 10 days after vaccination. In children age 4–6, there is no evidence for an increased risk in febrile seizures after the administration of Proquad compared to the separate administration of MMR and Varicella vaccines.[ 19] [ 20]
Proquad was approved for medical use in the United States in September 2005,[ 21] [ 22] [ 7] [ 2] [ 4]
Priorix Tetra was approved for medical use in Australia in November 2005,[ 3] [ 5]
^ "Measles virus vaccine/mumps virus vaccine/rubella virus vaccine/varicella virus vaccine (Proquad) Use During Pregnancy" .Drugs.com . 16 October 2019.Archived from the original on 19 October 2019. Retrieved26 January 2020 .^a b "Proquad measles mumps rubella varicella live virus vaccine injection vial with prefilled diluent syringe (126157)" .Therapeutic Goods Administration (TGA) . 26 May 2022.Archived from the original on 10 June 2024. Retrieved10 June 2024 .^a b "Priorix-Tetra vaccine 0.5mL powder for injection vial with diluent syringe (107286)" .Therapeutic Goods Administration (TGA) . 26 May 2022.Archived from the original on 31 January 2023. Retrieved10 June 2024 .^a b "Proquad Product information" .Health Canada Archived from the original on 10 June 2024. Retrieved10 June 2024 .^a b "Priorix Tetra Product information" .Health Canada Archived from the original on 10 June 2024. Retrieved10 June 2024 .^a b c d "Proquad- measles, mumps, rubella and varicella virus vaccine live injection, powder, lyophilized, for suspension" .DailyMed . 5 November 2024.Archived from the original on 21 April 2025. Retrieved7 October 2025 .^a b c d "Proquad EPAR" .European Medicines Agency (EMA)Archived from the original on 21 October 2020. Retrieved8 October 2020 .^ Kowalzik F, Faber J, Knuf M (August 2018). "MMR and MMRV vaccines".Vaccine . Progress in Vaccines.36 (36):5402– 5407.doi :10.1016/j.vaccine.2017.07.051 .PMID 28757060 . ^ Goodson JL, Seward JF (December 2015). "Measles 50 Years After Use of Measles Vaccine".Infectious Disease Clinics of North America .29 (4):725– 743.doi :10.1016/j.idc.2015.08.001 .PMID 26610423 . ^ "Measles: information about the disease and vaccines Questions and Answers" (PDF) .Immunization Action Coalition . November 2018.Archived (PDF) from the original on 28 November 2022. Retrieved28 November 2022 .^ Wellington K, Goa KL (2003). "Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella".Drugs .63 (19):2107– 2126.doi :10.2165/00003495-200363190-00012 .PMID 12962524 .S2CID 46973762 . ^ "GlaxoSmithKline Clinical Trial Register" .GlaxoSmithKline . Archived fromthe original on 30 November 2007. Retrieved19 October 2019 .^ "Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines" .European Medicines Agency (EMA) . 14 December 2012. Retrieved7 October 2025 .^ "Priorix-tetra" .The Australian Immunisation Handbook . 4 June 2018.Archived from the original on 19 October 2019. Retrieved18 October 2019 .^ Bauchau V, Van Holle L, Cohen C (November 2015)."Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra) Compared to Separate MMR + V Vaccination" .Drug Safety .38 (11):1095– 1102.doi :10.1007/s40264-015-0326-4 .PMC 4608986 PMID 26251259 . ^ "PEI Table of vaccines for measles with a valid marketing authorisation" .PEI, Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (in German). 19 October 2019.Archived from the original on 19 October 2019. Retrieved18 October 2019 .^ Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A (July 2007). "Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine".The Pediatric Infectious Disease Journal .26 (7):632– 638.doi :10.1097/INF.0b013e3180616c8f .PMID 17596807 .S2CID 41981427 . ^a b "MMRV (Measles, Mumps, Rubella & Varicella) VIS" . CDC. 21 May 2010. Archived fromthe original on 20 January 2015.^ Klein NP, Fireman B, Yih WK, Lewis E, Kulldorff M, Ray P, et al. (July 2010)."Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures" .Pediatrics .126 (1):e1– e8.doi :10.1542/peds.2010-0665 PMID 20587679 . ^ "CBER clinical review of studies submitted in support of licensure of Proquad" (PDF) . US Food and Drug Administration. August 2005. Archived fromthe original (PDF) on 6 May 2017. Retrieved16 December 2019 .^ "Proquad" .U.S.Food and Drug Administration (FDA) . Archived fromthe original on 23 July 2017. Retrieved8 October 2020 .^ "Proquad" .U.S.Food and Drug Administration (FDA) . STN: 125108. Archived fromthe original on 11 November 2020. Retrieved8 October 2020 .Centers for Disease Control and Prevention (CDC) (December 2005)."Notice to Readers: Licensure of a Combined Live Attenuated Measles, Mumps, Rubella, and Varicella Vaccine" (PDF) .MMWR Morb. Mortal. Wkly. Rep .54 (47):1212– 14.Archived (PDF) from the original on 20 January 2022. Retrieved26 January 2020 . Ma SJ, Li X, Xiong YQ, Yao AL, Chen Q (November 2015)."Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety" .Medicine .94 (44) e1721.doi :10.1097/MD.0000000000001721 .PMC 4915870 PMID 26554769 . World Health Organization (January 2009).The immunological basis for immunization series: module 7: measles (update 2009) .World Health Organization (WHO).hdl :10665/44038 ISBN 978-92-4-159755-5 World Health Organization (November 2010).The immunological basis for immunization series: module 16: mumps .World Health Organization (WHO).hdl :10665/97885 ISBN 978-92-4-150066-1 World Health Organization (December 2008).The immunological basis for immunization series: module 11: rubella .World Health Organization (WHO).hdl :10665/43922 ISBN 978-92-4-159684-8 World Health Organization (May 2008).The immunological basis for immunization series: Module 10: Varicella-zoster virus .World Health Organization (WHO).hdl :10665/43906 ISBN 978-92-4-159677-0 Ramsay M, ed. (December 2019)."Chapter 21: Measles" .Immunisation against infectious disease Archived from the original on 12 November 2019. Retrieved9 October 2020 . Ramsay M, ed. (April 2013)."Chapter 23: Mumps" .Immunisation against infectious disease Archived from the original on 12 November 2019. Retrieved9 October 2020 . Ramsay M, ed. (April 2013)."Chapter 28: Rubella" .Immunisation against infectious disease Archived from the original on 12 November 2019. Retrieved9 October 2020 . Ramsay M, ed. (March 2013)."Chapter 34: Varicella" .Immunisation against infectious disease Archived from the original on 12 November 2019. Retrieved9 October 2020 . Hamborsky J, Kroger A, Wolfe S, eds. (2015)."Chapter 13: Measles" .Epidemiology and Prevention of Vaccine-Preventable Diseases Centers for Disease Control and Prevention (CDC).ISBN 978-0-9904491-1-9 Archived from the original on 30 December 2016. Retrieved9 October 2020 . Hamborsky J, Kroger A, Wolfe S, eds. (2015)."Chapter 15: Mumps" .Epidemiology and Prevention of Vaccine-Preventable Diseases Centers for Disease Control and Prevention (CDC).ISBN 978-0-9904491-1-9 Archived from the original on 30 December 2016. Retrieved9 October 2020 . Hamborsky J, Kroger A, Wolfe S, eds. (2015)."Chapter 20: Rubella" .Epidemiology and Prevention of Vaccine-Preventable Diseases Centers for Disease Control and Prevention (CDC).ISBN 978-0-9904491-1-9 Archived from the original on 30 December 2016. Retrieved9 October 2020 . Hamborsky J, Kroger A, Wolfe S, eds. (2015)."Chapter 22: Varicella" .Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.:Centers for Disease Control and Prevention (CDC).ISBN 978-0-9904491-1-9 Archived from the original on 7 February 2015. Retrieved9 October 2020 . Roush SW, Baldy LM, Hall MA, eds. (March 2019)."Chapter 7: Measles" .Manual for the surveillance of vaccine-preventable diseases Centers for Disease Control and Prevention (CDC).Archived from the original on 1 August 2020. Retrieved9 October 2020 . Roush SW, Baldy LM, Hall MA, eds. (March 2019)."Chapter 9: Mumps" .Manual for the surveillance of vaccine-preventable diseases Centers for Disease Control and Prevention (CDC).Archived from the original on 1 August 2020. Retrieved9 October 2020 . Roush SW, Baldy LM, Hall MA, eds. (March 2019)."Chapter 14: Rubella" .Manual for the surveillance of vaccine-preventable diseases Centers for Disease Control and Prevention (CDC).Archived from the original on 1 August 2020. Retrieved9 October 2020 . Roush SW, Baldy LM, Hall MA, eds. (9 January 2020)."Chapter 17: Varicella" .Manual for the surveillance of vaccine-preventable diseases Centers for Disease Control and Prevention (CDC).Archived from the original on 1 August 2020. Retrieved9 October 2020 .
Development Classes Administration Vaccines
Inventors/ Controversy Related
N
Y (what is this?) (verify)
